Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 9/20 | 0.72 |
| ▸ | CTSL | P07711 | 9/20 | 0.72 |
| ▸ | CTSF | Q9UBX1 | 6/20 | 0.72 |
| ▸ | CTSK | P43235 | 15/20 | 0.67 |
| ▸ | CTSS | P25774 | 6/20 | 0.66 |
| ▸ | CTSV | O60911 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3265273 | 0.91 | CTSB (0.75) | CTSBCTSLCTSFCTSKCTSS | |
| SCHEMBL2848882 | 0.91 | CTSB (0.75) | CTSBCTSLCTSFCTSKCTSS | |
| SCHEMBL2927805 | 0.91 | CTSB (0.75) | CTSBCTSLCTSFCTSKCTSS | |
| SCHEMBL3757063 | 0.91 | CTSB (0.75) | CTSBCTSLCTSFCTSKCTSS | |
| SCHEMBL8121829 | 0.89 | CTSK (0.71) | CTSBCTSLCTSFCTSKCTSS | |
| SCHEMBL16377162 | 0.87 | CTSB (0.68) | CTSBCTSLCTSFCTSKCTSS | |
| SCHEMBL15827398 | 0.87 | CTSB (0.68) | CTSBCTSLCTSFCTSKCTSS | |
| SCHEMBL22733992 | 0.84 | CTSB (0.81) | CTSBCTSLCTSFCTSKCTSS | |
| SCHEMBL22733994 | 0.84 | CTSB (0.81) | CTSBCTSLCTSFCTSKCTSS | |
| SCHEMBL22733935 | 0.84 | CTSB (1.00) | CTSBCTSLCTSFCTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273913-B2 | Amidation process for the preparation of cathepsin K inhibitors | MERCK CANADA INC. (CA) | 2012-09-25 | — | — | US | disclosed |
| US-20100130782-A1 | AMIDATION PROCESS FOR THE PREPARATION OF CATHEPSIN K INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130782-A1 | AMIDATION PROCESS FOR THE PREPARATION OF CATHEPSIN K INHIBITORS | CTSK, CTSB, CTSF | CTSB 2/4885CTSL 11/4885CTSF 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.